Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

1. [Granuloma faciale and Takayasu arteritis in a child: a case report].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
   Article
2. Clinical updates of JAK inhibitors in cutaneous granulomatous diseases.Frontiers in immunology · 2025
   Review
3. Topical ruxolitinib for the treatment of granuloma faciale.JAAD case reports · 2023
   Article
4. A Case Series of Extrafacial Granuloma Faciale.Indian journal of dermatology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as